Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of $7.77 billion. The enterprise value is $8.16 billion.
Important Dates
The last earnings date was Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytokinetics has 122.26 million shares outstanding. The number of shares has increased by 11.00% in one year.
| Current Share Class | 122.26M |
| Shares Outstanding | 122.26M |
| Shares Change (YoY) | +11.00% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | 116.78% |
| Float | 121.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 86.71 |
| Forward PS | 97.30 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 93.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.88
| Current Ratio | 6.88 |
| Quick Ratio | 6.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.96 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -24.93% |
| Return on Invested Capital (ROIC) | -41.55% |
| Return on Capital Employed (ROCE) | -44.26% |
| Revenue Per Employee | $175,122 |
| Profits Per Employee | -$1.51M |
| Employee Count | 498 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.76% in the last 52 weeks. The beta is 0.59, so Cytokinetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +34.76% |
| 50-Day Moving Average | 63.00 |
| 200-Day Moving Average | 46.05 |
| Relative Strength Index (RSI) | 51.41 |
| Average Volume (20 Days) | 2,097,760 |
Short Selling Information
The latest short interest is 13.34 million, so 10.91% of the outstanding shares have been sold short.
| Short Interest | 13.34M |
| Short Previous Month | 12.95M |
| Short % of Shares Out | 10.91% |
| Short % of Float | 10.97% |
| Short Ratio (days to cover) | 7.60 |
Income Statement
In the last 12 months, Cytokinetics had revenue of $87.21 million and -$751.94 million in losses. Loss per share was -$6.32.
| Revenue | 87.21M |
| Gross Profit | -318.05M |
| Operating Income | -572.93M |
| Pretax Income | -751.94M |
| Net Income | -751.94M |
| EBITDA | -563.29M |
| EBIT | -572.93M |
| Loss Per Share | -$6.32 |
Full Income StatementBalance Sheet
The company has $962.54 million in cash and $1.35 billion in debt, giving a net cash position of -$387.72 million or -$3.17 per share.
| Cash & Cash Equivalents | 962.54M |
| Total Debt | 1.35B |
| Net Cash | -387.72M |
| Net Cash Per Share | -$3.17 |
| Equity (Book Value) | -521.12M |
| Book Value Per Share | -4.26 |
| Working Capital | 835.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$432.93 million and capital expenditures -$20.45 million, giving a free cash flow of -$453.38 million.
| Operating Cash Flow | -432.93M |
| Capital Expenditures | -20.45M |
| Free Cash Flow | -453.38M |
| FCF Per Share | -$3.71 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -656.95% |
| Pretax Margin | -862.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.00% |
| Shareholder Yield | -11.00% |
| Earnings Yield | -9.68% |
| FCF Yield | -5.84% |
Dividend DetailsAnalyst Forecast
The average price target for Cytokinetics is $82.38, which is 29.65% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $82.38 |
| Price Target Difference | 29.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 121.45% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
Cytokinetics has an Altman Z-Score of -2.2 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.2 |
| Piotroski F-Score | 3 |
